Physician profile
Caroline Lam
NPI 1205365269
$717.33
in general payments reported to CMS, 2019-2025
11 companies · $84.46 in 2025
The $84.46 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $110 · 2021: $39.71 · 2022: $173 · 2023: $60.86 · 2024: $249 · 2025: $84.46.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $394.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $394.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $285.40 | 2023-2024 | Qelbree |
| Janssen Pharmaceuticals, INC | $132.50 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $69.38 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $52.37 | 2021-2025 | |
| Lundbeck LLC | $47.50 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $25.80 | 2022 | |
| Vanda Pharmaceuticals INC. | $25.16 | 2025 | Fanapt |
| Brainsway USA INC | $24.50 | 2023 | |
| Sunovion Pharmaceuticals INC. | $21.72 | 2022 | |
| Abbott Laboratories | $17.67 | 2025 | Cardiomems |
| Tempus Ai, INC | $15.33 | 2025 | Tempus Pixel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caroline Lam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.